VCP979, a novel p38MAPK inhibitor, attenuates inflammatory response and improve cardiac function post-myocardial infarction
29 August 2017 (08:30 - 12:30)
Organised by:
Abstract
Slides
About the speaker

Baker Heart and Diabetes Institute, Melbourne (Australia)
28 More presentations in this session
Access the full session
The Event
ESC Congress 2017
29 August 2017
08:30 CET
